To our knowledge, this is the first study evaluating the irritancy potential of different types of copper compounds at the cellular, genomic and proteomic levels using keratinocyte cell lines
Professor Jastreboffs research contributions include: Principal investigator for GLP3 phase 2 obesity trial demonstrating 24.2% weight loss Leadership in clinical research examining triple hormone receptor agonists Extensive investigations of incretin-based therapies for obesity and metabolic disease Pioneering work on combination approaches to weight management Studies examining neurobiological mechanisms underlying obesity pharmacotherapy Her work has helped establish GLP3 as one of the most promising next-generation obesity treatments in clinical development, contributing to the scientific foundation for multi-pathway metabolic interventions
Additionally, cortistatin activates the MrgX2 receptor, a Mas-related G protein-coupled receptor potentially involved in immune regulation
For comparison, GHK-Cu differs from NAD+ therapy, which targets cellular energy pathways rather than tissue remodeling
Collagen peptides can supplement dietary protein
Proper storage and handling practices help preserve product integrity, stability, and overall quality
